Clinical characteristics of euDKA cases
Case patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age (years) | 40 | 58 | 27 | 28 | 31 | 55 | 26 | 39 | 64 | ||||
Sex | Female | Male | Female | Female | Female | Female | Female | Female | Female | ||||
T1/T2 | T1 | T2 | T1 | T1 | T1 | T1 | T1 | T1 | T2 | ||||
MDI/CSII | MDI | N/A | MDI | CSII | CSII | CSII | CSII | CSII | N/A | ||||
Duration (years) | 17 | 2 | 25 | 6 | 15 | 18 | 13 | 26 | 6 | ||||
BMI (kg/m2) | 26.5 | 26.5 | 24.3 | 25.9 | 33.2 | 22.0 | 22.0 | 26.1 | 32.8 | ||||
Prior A1C [% (mmol/mol)] | 11.4 (101.1) | 9.8 (83.6) | 7.8 (61.7) | 8.0 (63.9) | 7.0 (53.0) | 7.2 (55.2) | 6.6 (48.6) | 7.0 (53.0) | 7.8 (62.0) | ||||
Canagliflozin dose (mg) | 300 | 300 | 300 | 100 | 300 | 100 | 300 | 300 | 150 | 300 | 300 | ||
Potential contributors | URI | Surgery 1 week prior | URI, alcohol | Alcohol | Alcohol | Exercise, alcohol | Exercise | GI | None | URI | Surgery 12 h prior | ||
Insulin dose reduction just prior to euDKA | Yes | N/A | Yes | No | Yes | Yes | Yes | Unknown | No | No | No | Yes | N/A |
Presenting plasma glucose [mg/dL (mmol/L)] | 220 (12.2) | 150 (8.3) | 150 (8.3) | 96 (5.3) | 224 (12.4) | 158 (8.8) | ∼125 (∼6.9) | 203 (11.3) | 190 (10.6) | 150 (8.3) | 233 (12.9) | 169 (9.4) | |
pH | 6.9 | 7.12 | 6.89 | 7.15 | |||||||||
Pco2 (mmHg) | 10 | 26 | |||||||||||
Bicarbonate (mEq/L) | 6 | 10 | 6 | 11 | 18 | 15 | 9 | 9 | 13 and then 5 | ||||
Anion gap (mEq/L) | 25 | 17 | 35 | 22 | 18 | 26 | 21 | 24 | 16 and then 19 | ||||
Ketones* | Yes (serum and urine) | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes (serum and urine) |
Where treated | ICU | ICU | ICU | Outpt. | ICU | Inpt. | Outpt. | ICU | ICU | Outpt. | Outpt. | ICU | ICU |
CSII, continuous subcutaneous insulin infusion; GI, gastrointestinal; Inpt., inpatient; N/A, not available; Outpt., outpatient.
↵*Urine ketones were strongly positive in all cases.